ALK and non-small cell lung carcinoma: EGFR or HER4 inhibition may also be an effective strategy to overcome ALK inhibitor resistance in NB, as EGFR activation by HB-EGF caused adaptive resistance to lorlatinib in NSCLC [253], and pan-HER inhibitor dactomitinib prevented the emergence of drug tolerant persister cells in ALK-positive NSCLC [254].